Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Published:2019-08-22 Issue:22 Volume:25 Page:6644-6652
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Gray Jhanelle E.,Okamoto Isamu,Sriuranpong Virote,Vansteenkiste Johan,Imamura Fumio,Lee Jong Seok,Pang Yong-Kek,Cobo Manuel,Kasahara Kazuo,Cheng Ying,Nogami Naoyuki,Cho Eun Kyung,Su Wu Chou,Zhang Guili,Huang Xiangning,Li-Sucholeiki Xiaocheng,Lentrichia Brian,Dearden Simon,Jenkins Suzanne,Saggese Matilde,Rukazenkov Yuri,Ramalingam Suresh S.

Funder

AstraZeneca, Cambridge, United Kingdom, themanufacturer of osimertinib

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors;Future Oncology;2024-09-04

2. Finding One Treatment for All Advanced EGFR-positive NSCLC—An Infinite Task;Journal of Thoracic Oncology;2024-06

3. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.;Lung Cancer: Targets and Therapy;2024-06

4. The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non–small-cell Lung Cancer Patients: The FOCUS-C Study;Clinical Lung Cancer;2024-06

5. Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes;Journal of Personalized Medicine;2024-04-24